Skip to main content

Biogen's other Alzheimer's drug fails in late-stage trial

Less than two weeks after the historic approval of Aduhelm, a different Alzheimer's disease drug developed by Biogen Inc. (Nasdaq: BIIB) has failed in a late-stage clinical trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.